Neoadjuvant Chemotherapy + Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy ± Adjuvant Chemotherapy for Locoregionally Advanced NPC: an Update Meta-Analysis and Efficacy-Toxicity Joint Analysis.
S. Liu,D. Xie,S. Zhou,C. Xu,Z. Ye,G. Wang,S. Ding,Y. Xia
DOI: https://doi.org/10.1093/annonc/mdy438.018
IF: 51.769
2018-01-01
Annals of Oncology
Abstract:Background: We aimed to reappraise the actual effect on multiple survival and toxicity outcomes of NACT + CCRT versus CCRT ± AC. Methods: PROSPERO number were CRD42017078857.Databases searched: PubMed, EMBASE, WOS and The Cochrane Library. Cochrane recommended criteria assessed methodological quality of included studies. Fixed or random effects model used Revman 5.3 to pooled HR, OR and I2. The primary outcome were OS, LRFS and DMFS; secondary outcomes were PFS, DFS and G3-4 adverse events (AE). Supplementary network meta-analysis (NMA) used R, Stata and ITC software. Results: Until 8 May 2018,10 RCTs and 6 cohorts including 4652 patients with low to moderate risk of bias were analyzed. Pooled estimates demonstrated a benefit in OS (HR 0.79 [0.62-0.99], I2=42%), DMFS (HR 0.82 [0.69-0.98], I2=0%), PFS (HR 0.66 [0.52-0.84], I2=0%) and DFS (HR 0.71[0.55-0.92], I2=0%), no benefit was found in LRFS (HR 1.06 [0.82-1.36], I2=0%), with more frequent acute AE (thrombocytopenia (OR = 3.03 [1.88, 4.87], I2=4%), anemia (OR = 1.85 [1.30, 2.61],I2=30%), leukopenia (OR = 2.28 [1.39, 3.74], I2=71%), neutropenic fever (OR = 8.77 [1.56, 49.23], I2=0%) in the NACT group. Subgroup analysis for OS, significant difference were between RCTs and cohorts (HR 0.66 [0.54, 0.80] vs 1.23 [0.94, 1.61], Pinter =0.0003) ; in clinical stage subgroup for LRFS, II-III-IV arm presented a significant harm of NACT (HR 2.69 [1.34-5.41], Pinter=0.005) while no significant difference in III-IV and modified III-IV arms (HR 1.13 [0.78-1.62] and HR 0.71 [0.47-1.06], respectively). Supplementary NMA showed TP as NACT had the highest SUCRA values (89.8% and 80.5%, respectively) or OS and anemia; DDP as CCRT plus PF as AC for thrombocytopenia (SUCRA=81.2%), CBP as CCRT for leukemia (SUCRA=93.8%). Cluster analysis showed NACT (TP or TPF) significantly improved OS with the lowest rate of G3-4 anemia while thrombocytopenia or leukemia combined with OS, no upper right best treatments were found. Conclusions: NACT delays disease progression and may improve OS for LA NPC. More effective and better tolerated agent options and specific subgroup selection for NACT phase need further exploration. Legal entity responsible for the study: Professor Yunfei Xia. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.